Please assess the completion status of the following clinical trial:

Trial Title: Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects as determined by no clinically significant deviation from normal in medical history, Physical Examination, vital signs, 12-lead ECG, and clinical laboratory determinations~* Body mass index (BMI) of 18 to 30 kg/m2~* Men and women, ages 18 to 45 years~* Women of childbearing potential must use acceptable methods of highly effective birth control~Exclusion Criteria:~* History of chronic or recurrent urinary tract infection for females~* History of allergies or adverse reactions to Dipeptidyl peptidase-IV (DPP4) or Sodium-glucose transporter type 2 (SGLT2) inhibitors~* Any significant acute or chronic medical illness~* Current or recent gastrointestinal disease~* Any major surgery within 4 weeks of study drug administration~* Prior exposure to saxagliptin or dapagliflozin or related drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin) (Type: EXPERIMENTAL): Treatment A: Saxagliptin 5mg, Tablet, Oral; Single dose Treatment B: Dapagliflozin 10mg, Tablet, Oral; single dose Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; single dose
- A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin (Type: EXPERIMENTAL): Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
- B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin) (Type: EXPERIMENTAL): Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose. Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose
- B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin (Type: EXPERIMENTAL): Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
- C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin (Type: EXPERIMENTAL): Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
- C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin (Type: EXPERIMENTAL): Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, Once daily, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).